BioMarin Announces First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
BioMarin Pharma (BMRN) Misses Q1 EPS by 14c
April 25, 2019 4:11 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of ($0.32), $0.14 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $400 million versus the consensus estimate of $389.69 million.
2019 Full-Year Financial Guidance unchangedFor earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
... More